Preoperative screening for nasal carriage of methicillin-resistant Staphylococcus aureus in patients undergoing general thoracic surgery

Yoshimasa Mizuno1, Koyo Shirahashi2, Hirotaka Yamamoto2, Mitsuyoshi Matsumoto2, Yusaku Miyamoto2, Hiroyasu Komuro2, Kiyoshi Doi2, and Hisashi Iwata3

1 Department of General Thoracic Surgery, Chuno Kosei Hospital, Japan
2 Department of General and Cardiothoracic Surgery, Graduate School of Medicine, Gifu University, Japan
3 Department of General Thoracic Surgery, Center of Respiratory Disease, Gifu University Hospital, Japan

Abstract

Objectives: Nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) is a risk factor for surgical site infections (SSIs). However, few studies have evaluated the rate of nasal carriage of MRSA and its effect on SSIs in patients undergoing general thoracic surgery. We investigated the importance of preoperative screening for nasal carriage of MRSA in patients undergoing general thoracic surgery.

Patients and Methods: We retrospectively analyzed 238 patients with thoracic diseases who underwent thoracic surgery. We reviewed the rates of nasal carriage of MRSA and SSIs.

Results: Results of MRSA screening were positive in 11 of 238 patients (4.6%), and 9 of these 11 patients received nasal mupirocin. SSIs occurred in 4 patients (1.8%). All 4 patients developed pneumonia; however, MRSA pneumonia occurred in only 1 of these 4 patients. No patient developed wound infection, empyema, and/or mediastinitis. SSIs did not occur in any of the 11 patients with positive results on MRSA screening.

Conclusions: The rates of nasal carriage of MRSA and SSIs were low in this case series. Surveillance is important to determine the prevalence of MRSA carriage and infection in hospitals, particularly in the intensive care unit. However, routine preoperative screening for nasal carriage of MRSA is not recommended in patients undergoing general thoracic surgery.

Key words: methicillin-resistant Staphylococcus aureus, preoperative screening, surgical site infection

Introduction

Staphylococcus aureus is a well-known dangerous bacterium affecting humans1. Since methicillin-resistant S. aureus (MRSA) was first isolated by Jevons and Barber2,3, it has shown a progressive increase in prevalence across hospitals and communities4,5. Clinically, MRSA-associated infections are difficult to treat owing to the high antibiotic resistance of MRSA strains. Recently, MRSA-associated surgical site infections (SSIs) are considered serious medical complications, and appropriate screening and prophylactic intervention are recommended in patients undergoing open heart and orthopedic surgery6–9. Previous studies have investigated the duration of hospitalization, medical costs, and patient outcomes associated with SSIs10,11. However, to our knowledge, only 1 study has investigated the efficacy of screening for and prophylaxis against nasal carriage of MRSA in patients undergoing general thoracic surgery. Unfortunately, the results of that study were inconclusive12. We investigated the prevalence rate of nasal carriage of MRSA and the rate of SSI-induced comorbidities in patients undergoing general thoracic surgery.

Patients and Methods

Patients: Between April 2014 and December 2017, 279 consecutive patients with thoracic diseases underwent surgical treatment at the Chuno Kosei Hospital in Gifu, Japan.
Of these 279 patients, 238 (85.3%) underwent screening for nasal carriage of MRSA. MRSA screening using anterior nares swabs is routinely performed in all patients scheduled to admit to the intensive care unit (ICU) postoperatively, as part of an ongoing Chuno Kosei Hospital surveillance program. Screening was not performed in 41 patients among the patients who did not plan to enter the ICU. We retrospectively analyzed the clinical data of patients undergoing screening. The following data were collected for each patient to determine the usefulness of preoperative screening of nasal carriage of MRSA: demographics, diagnosis, surgical procedures, results of nasal swabs, and occurrence of SSI. This study was approved by the Chuno Kosei Hospital Ethics Committee for Clinical Research (approval No. H30-3).

Preoperative and perioperative management: Nasal swabs were obtained from the patients who were referred to our department. Patients who showed positive results on MRSA screening received treatment with 2% mupirocin ointment. Bronchoalveolar lavage fluid cultures were examined in patients who underwent preoperative bronchoscopy. However, no patient underwent intensive preoperative skin preparation with the use of chlorhexidine gluconate soap, even among those with positive results on MRSA screening. All patients received prophylactic antimicrobial treatment with a single dose of cefazolin (1 g) that was administered preoperatively (an hour before the surgical incision was made). Additional doses were administered every 3 hours intraoperatively. Postoperative prophylaxis was administered 8 hours after the last intraoperative administration of the drug.

Postoperative management: Chest radiographs were obtained on each postoperative day. Blood tests including complete blood cell counts and serum levels of C-reactive protein (CRP) were performed on postoperative days 1, 2, 3, 5, 7, and 9. Chest computed tomography (CT) was not routinely performed.

Additional tests were performed for further evaluation depending on the patient’s clinical course rather than for the assessment of all abnormal symptoms and signs that suggested SSIs. Patients with fever or an elevated white blood cell count or CRP underwent additional testing including whole body CT, serum procalcitonin levels, β-d-glucan assay, Aspergillus and Candida antigen testing, as well as sputum and blood cultures for the assessment of infections. Broad-spectrum antibiotics were administered until the results of the aforementioned tests were obtained. Antimicrobial therapy was changed as necessary according to the results of these tests.

Results

Details regarding patient characteristics and preoperative diagnosis and surgical procedures are shown in Tables 1 and 2, respectively. Results of screening for nasal carriage of MRSA were positive in 11 of 238 patients (4.6%). Details of nasal cavity cultures are shown in Table 3. Nine of these 11 patients were treated with nasal mupirocin ointment. Successful decolonization was not confirmed in any patient. Two patients could not be administered mupirocin because the drug supply was discontinued. SSIs occurred in 4 of 238 patients (1.8%). All 4 patients developed pneumonia, and only 1 of these 4 patients developed MRSA pneumonia. However, all patients were successfully treated with antibacterial therapy. No patient developed wound infection, empyema, and/or mediastinitis. The 4 patients who developed pneumonia were all heavy ex-smokers (>40 pack year), but denied any underlying disease or risk factors as shown in Table 1. These 4 patients underwent lobectomy for primary lung cancer. SSIs did not occur in any of the 11 patients with a positive result on MRSA screening, regardless of whether they received nasal mupirocin treatment.

Discussion

SSIs negatively affect patient outcomes by increasing morbidity and mortality rates and diminishing patients’ quality of life. SSIs lead to cost escalation related to prolonged hospitalization, with additional expenditure involving medical personnel and treatment costs. Therefore, various screening and prophylactic methods are being explored to prevent SSIs. According to the American Society of Health-System Pharmacists guideline, an ideal antimicrobial agent for surgical prophylaxis should fulfill the following criteria: (1) prevent SSIs, (2) prevent SSI-related morbidity and mortality, (3) reduce the duration of hospitalization and
health care costs, (4) cause no adverse effects, and (5) not adversely affect the patient’s commensal flora or that of the hospital environment\(^{13}\). Perioperative systemic prophylactic antimicrobial therapy is routinely administered for SSI prevention, and cefazolin or ampicillin-sulbactam is commonly recommended (clindamycin or vancomycin is an acceptable alternative in patients with a documented β-lactam allergy)\(^{14–17}\). In this study, no patient was allergic to β-lactam antibiotics, and all patients received a single dose of cefazolin (1 g). We did not adjust the dosage on the basis of a patient’s weight.

The efficacy of preoperative MRSA screening and nasal decolonization is unclear; however, this issue has gained much attention in recent years\(^{14–17}\). A randomized control trial showed the preventive effect of SSIs among \textit{S. aureus} carriers in general, cardiothoracic, and neurosurgical patients. The effectiveness of such screening was shown in studies that were limited to patients undergoing open heart and orthopedic surgery\(^{13}\). These studies were not supported by a high level of evidence, the degree of recommendation was not high even in the patients undergoing open heart and orthopedic surgery\(^{13}\). Routine screening for nasal carriage of \textit{S. aureus} (including MRSA) is not recommended in patients undergoing general thoracic surgery, and the single study that investigated this issue could not conclusively prove the usefulness of such screening\(^{13}\). Open heart surgery and orthopedic surgery are considered “clean” surgeries. However, general thoracic surgery, which is considered a “clean-contaminated” surgery, may require a different degree of perioperative asepsis.

The types of thoracic diseases and surgical procedures performed for primary lung cancer in this study are shown in Table 2. These figures are nearly similar to those reported in Japan in 2014\(^{18}\). The disease distribution and surgical stress are not significantly different from other studies. SSI rates in the first postoperative month reportedly vary from 1% to 5\(^{18}\). Although the SSI rate in Japan is unclear, the SSI-related mortality rate (related to pneumonia and pyothorax) following lung cancer operations is very low (0.13\%)\(^{19}\). In this study, SSI and mortality rates were 1.8% and 0%, respectively, which concurs with previous reports. We did not confirm whether decolonization was successful in our patients; thus, we could not determine the accurate MRSA colonization rate at the time of operation. Although surgery was performed in as many as 11 patients with MRSA colonization, no patient developed SSIs including those caused by MRSA. The colonization rates of methicillin-sensitive \textit{S. aureus} and MRSA were 14.3% and 4.6%, respectively. The colonization and SSI rates were both low; therefore, we speculated that preoperative screening for nasal carriage of MRSA is not necessary in patients undergoing general thoracic surgery.

Prevention of healthcare-associated infections has been widely discussed in the literature\(^{18}\). Screening for nasal carriage of MRSA shows a high specificity and negative predictive value to rule out MRSA pneumonia, particularly in patients with community-acquired and healthcare-associated pneumonia\(^{20}\). Moreover, a few reports have shown the importance of screening for nasal carriage of MRSA in patients with infections admitted to ICUs\(^{21, 22}\). A previous report has shown that \textit{S. aureus} nasal colonization rates decreased from 32.4% in 2001–2002 to 28.6% in 2003–2004. However, MRSA nasal colonization rates increased from 0.8% to 1.5% in the United States\(^{23}\). In the present study, colonization rates of \textit{S. aureus} and MRSA were 14.3% and 4.6%, respectively, and the MRSA colonization rates appear to have increased gradually. Another retrospective cohort

| Table 2 | Preoperative diagnosis and surgical procedures performed in the study population |
|---------|--------------------------------------------------------------------------------|
| Primary lung cancer | 152 (63.9%) |
| Metastatic lung cancer | 23 (9.7%) |
| Lung benign tumor | 12 (5.0%) |
| Lung cyst infection | 1 (0.4%) |
| Pulmonary resections | 188 |
| Partial resection | 37 |
| Segmentectomy | 15 |
| Lobectomy | 134 |
| Pneumonectomy | 2 |
| Pneumothorax | 34 (14.3%) |
| VATS bullectomy | 34 |
| Mediastinal and chest wall tumors | 13 (5.5%) |
| Thymothymectomy | 6 |
| Tumor resection | 3 |
| Biopsy | 4 |
| Malignant mesothelioma | 1 (0.4%) |
| Extrapleural pneumonectomy | 1 |
| Acute empyema | 2 (0.8%) |
| VATS debridement | 2 |
| Total | 238 (100%) |

VATS: video assisted thoracic surgery.

| Table 3 | Organisms detected in nasal cavity cultures |
|---------|-------------------------------------------|
| MRSA | 11 (4.6%) |
| MSSA | 34 (14.3%) |
| CNS | 122 (51.3%) |
| Corynebacterium sp. | 121 (50.8%) |
| Others | 5 (2.1%) |
| Negative | 15 (6.3%) |

CNS: coagulase-negative \textit{Staphylococcus}; MSSA: methicillin-sensitive \textit{Staphylococcus aureus}; MRSA: methicillin-resistant \textit{Staphylococcus aureus}. |
study performed in Scotland reported that selective screening in patients undergoing elective surgery or admitted to the ICU between January 2006 and July 2008 and for all adult medical, surgical, and ICU overnight admissions between August 2009 and December 2011 yielded MRSA-positive rates of 6.9% and 3.1%, respectively. Moreover, the detection rate of MRSA colonization increases with swabs obtained from multiple body sites. Reportedly, a universal protocol for MRSA screening upon admission and antibiotic stewardship is useful to reduce bacteremia and early mortality rates. The detection and treatment of MRSA colonization have improved, which consequently may have reduced infection and transmission of MRSA to other patients. Screening should be performed on the basis of changes in time flow and regionality. Additionally, surveillance of MRSA colonization may be more suitable in specific groups of patients, for example, those who are admitted to the ICU and in immunocompromised hosts, although this issue could not be adequately verified in this study.

Limitations

Ideally, a prospective trial is needed to evaluate the necessity of preoperative screening for nasal carriage of MRSA in patients undergoing general thoracic surgery. However, only a few patients demonstrate nasal MRSA colonization. Additionally, patients’ characteristics and surgical procedures differ across studies; therefore, it is difficult to design such a prospective study. Thus, we performed retrospective cohort study. The retrospective design and small sample size are drawbacks of this study; thus, large-scale studies are warranted for further assessment.

Conclusions

Although it may be necessary to strengthen surveillance of immunocompromised hosts, hospitals, and medical personnel, universal preoperative screening for nasal carriage of MRSA is not recommended in patients undergoing general thoracic surgery.

Conflict of Interest: All authors have no conflicts of interest.

References

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520–532. [Medline] [CrossRef]
2. Jevons MP. Celbenin-resistant Staphylococci. BMJ 1961; 1: 124–125. [CrossRef]
3. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961; 14: 385–393. [Medline] [CrossRef]
4. Cafferkey MT, Hone R, Coleman D, et al. Methicillin-resistant Staphylococcus aureus in Dublin 1971–84. Lancet 1985; 2: 705–708. [Medline] [CrossRef]
5. Calfee DP. Trends in community versus health care-acquired methicillin-resistant staphylococcus aureus infections. Curr Infect Dis Rep 2017; 19: 48. [Medline] [CrossRef]
6. Schweizer M, Perencevich E, McDanel J, et al. Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis. BMJ 2013; 346: f2743. [Medline] [CrossRef]
7. Humphreys H, Becker K, Dohmen PM, et al. Staphylococcus aureus and surgical site infections: benefits of screening and decolonization before surgery. J Hosp Infect 2016; 94: 295–304. [Medline] [CrossRef]
8. Boyce JM, Potter-Bynoe G, Dziobek L. Hospital reimbursement patterns among patients with surgical wound infections following open heart surgery. Infect Control Hosp Epidemiol 1990; 11: 89–93. [Medline] [CrossRef]
9. Saraswat MK, Magruder JT, Crawford TC, et al. Preoperative staphylococcus aureus screening and targeted decolonization in cardiac surgery. Ann Thorac Surg 2017; 104: 1349–1356. [Medline] [CrossRef]
10. Green JW, Wenzel RP. Postoperative wound infection: a controlled study of the increased duration of hospital stay and direct cost of hospitalization. Ann Surg 1977; 185: 264–268. [Medline] [CrossRef]
11. Badia JM, Casey AL, Petrosillo N, et al. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect 2017; 96: 1–15. [Medline] [CrossRef]
12. Grimmer LE, Stafford TS, Milman S, et al. Efficacy of pre-operative nasal staphylococcus aureus screening and chlorhexidine chest scrub in decreasing the incidence of post-resection empyema. Surg Infect (Larchmt) 2014; 15: 118–122. [Medline] [CrossRef]
13. Bratzler DW, Dellinger EP, Olsen KM, et al. American Society of Health-System Pharmacists (ASHP) Infectious Diseases Society of America (IDSA) Surgical Infection Society (SIS) Society for Healthcare Epidemiology of America (SHEA) Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14: 73–156. [Medline] [CrossRef]
14. Sai N, Laurent C, Strale H, et al. Efficacy of the decolonization of methicillin-resistant Staphylococcus aureus carriers in clinical practice. Antimicrob Resist Infect Control 2015; 4: 56. [Medline] [CrossRef]
15. Hetem DJ, Bootma MC, Bonten MJ. Prevention of surgical site infections: decontamination with mupirocin based on preoperative screening for staphylococcus aureus carriers or universal decontamination? Clin Infect Dis 2016; 62: 631–636. [Medline] [CrossRef]
16. Liu Z, Norman G, Iheozor-Ejiofor Z, et al. Nasal decontamination for the prevention of surgical site infection in Staphylococcus aureus carriers. Cochrane Database Syst Rev 2017;
17. Perl TM, Cullen JJ, Wenzel RP, et al. Mupirocin And The Risk Of Staphylococcus Aureus Study Team Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002; 346: 1871–1877. [Medline] [CrossRef]

18. Masuda M, Okumura M, Doki Y, et al. Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 2016; 64: 665–697. [Medline] [CrossRef]

19. Yokoe DS, Anderson DJ, Berenholtz SM, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates. Infect Control Hosp Epidemiol 2014; 35(Suppl 2): S21–S31. [Medline] [CrossRef]

20. Parente DM, Cunha CB, Mylonakis E, et al. The clinical utility of Methicillin-Resistant Staphylococcus Aureus (MRSA) nasal screening to rule out MRSA Pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. Clin Infect Dis 2018; 67: 1–7 [CrossRef]. [Medline]

21. Huang SS, Septimus E, Platt R. Targeted decolonization to prevent ICU infections. N Engl J Med 2013; 369: 1470–1471. [Medline] [CrossRef]

22. Kao KC, Chen CB, Hu HC, et al. Risk factors of methicillin-resistant staphylococcus aureus infection and correlation with nasal colonization based on molecular genotyping in medical intensive care units: a prospective observational study. Medicine (Baltimore) 2015; 94: e1100. [Medline] [CrossRef]

23. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001–2004. J Infect Dis 2008; 197: 1226–1234. [Medline] [CrossRef]

24. Lawes T, Edwards B, López-Lozano JM, et al. Trends in Staphylococcus aureus bacteraemia and impacts of infection control practices including universal MRSA admission screening in a hospital in Scotland, 2006–2010: retrospective cohort study and time-series intervention analysis. BMJ Open 2012; 2: e000797 [CrossRef]. [Medline]

25. Chipolombwe J, Török ME, Mbelle N, et al. Methicillin-resistant Staphylococcus aureus multiple sites surveillance: a systemic review of the literature. Infect Drug Resist 2016; 9: 35–42. [Medline]